image credit: Pixabay

US government to pay $5.3bn for Pfizer‘s Paxlovid

November 22, 2021


The supply agreement will see the government receive ten million treatment courses of Paxlovid, pending regulatory approval, starting later in the year and into 2022.

Paxlovid is a combination of PF-07321332 and ritonavir; PF-07321332 blocks the action of a protease that the coronavirus needs to replicate while ritonavir is an antiretroviral used commonly to treat HIV infections that slows the breakdown of PF-07321332, thereby increasing its duration of action.

Read More on PMLiVE